Condition
Tularemia
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (3)
Trial Status
Completed2
Not Yet Recruiting1
Withdrawn1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06859619Not ApplicableNot Yet Recruiting
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
NCT05300425Completed
Seroprevalence of Leptospirosis in Val Müstair, Switzerland
NCT03867162Phase 2WithdrawnPrimary
FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)
NCT00787826Phase 2UnknownPrimary
Continued Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
NCT00584844Phase 2CompletedPrimary
Safety and Immunogenicity Study of a Live Francisella Tularensis Vaccine
Showing all 5 trials